Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2024; 15(7): 859-866
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.859
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.859
Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
Shi-Qiong Zhou, Peng Wan, Sen Zhang, Yuan Ren, Hong-Tao Li, Qing-Hua Ke, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China
Co-first authors: Shi-Qiong Zhou and Peng Wan.
Author contributions: Ke QH designed the study; Zhou SQ, Wan P performed the research; Li HT and Ren Y contributed new reagents/analytical tools; Zhang S analyzed the data; Zhou SQ and Wan P wrote the paper; All authors have read and approved the submitted manuscript. Zhou SQ and Wan P contributed equally to this work and served as co-first authors.
Institutional review board statement: The present study was approved by the Ethics Committee of The First Affiliated Hospital of Yangtze University (No. KY202429) and was performed according to the Declaration of Helsinki.
Informed consent statement: Exemption from informed consent form was approved after review by the Ethics Committee of the First Affiliated Hospital of Yangtze University.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All datasets during and/or analyzed during the current study are available from the corresponding author upon reasonable request at 3803354759@qq.com .
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Qing-Hua Ke, MM, PhD, Additional Professor, Chief Physician, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, No. 40 Jinglong Road, Shashi District, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com
Received: May 2, 2024
Revised: June 3, 2024
Accepted: June 26, 2024
Published online: July 24, 2024
Processing time: 74 Days and 23.6 Hours
Revised: June 3, 2024
Accepted: June 26, 2024
Published online: July 24, 2024
Processing time: 74 Days and 23.6 Hours
Core Tip
Core Tip: The article presents an insightful exploration of a study of the combination of sintilimab with S-1 and gemcitabine concurrent radiotherapy for locally advanced pancreatic cancer (LAPC). The observation group had significantly longer median progression-free survival and overall survival than the control group. The occurrence of severe adverse events did not exhibit a statistically significant difference between the observation group and the control group, with a P value greater than 0.05. It is considered a promising, effective, and well-tolerated treatment for LAPC.